Biogen Inc.
BIIB Healthcare Drug Manufacturers - General NASDAQ
$183.82
$-4.26 (-2.26%)
Open: $186.25 | High: $186.25 | Low: $181.31 | Prev Close: $188.08
Market Cap: $26.98B
Volume: 388K | Avg: 1.7M
Last updated: March 06, 2026 at 08:00 PMInvestment Rating
Neutral
Overall Score: 60/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 605
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | 20.94 |
| P/B Ratio | 1.48 |
| P/S Ratio | 2.75 |
| EPS | $8.78 |
| Beta | 0.15 |
| Shares Outstanding | 146.76M |
| 52-Week High | $202.41 |
| 52-Week Low | $110.04 |
| SMA 50 | $182.71 |
| SMA 200 | $153.80 |
| Next Earnings | April 30, 2026 01:30 PM ET |
Financial Ratios
| Gross Margin | 70.5% |
| Operating Margin | 19.1% |
| Net Margin | 13.2% |
| ROE | 7.3% |
| ROA | 4.4% |
| Debt/Equity | 0.38 |
| Current Ratio | 2.68 |
| Quick Ratio | 2.03 |
Balance Sheet
| Total Assets | $29.44B |
| Total Liabilities | $11.18B |
| Total Equity | $18.26B |
|
|
|
| Cash | $3.01B |
| Total Debt | $6.95B |
| Net Debt | $3.94B |
Income Statement
| Revenue | $9.81B |
| Gross Profit | $6.91B |
| Operating Income | $1.88B |
| Net Income | $1.29B |
|
|
|
| EBITDA | $3.10B |
| Revenue/Share | $66.88 |
Cash Flow
| Operating CF | $2.20B |
| CapEx | $153.80M |
| Free Cash Flow | $2.05B |
|
|
|
| Book Value/Share | $124.45 |
| Tangible Book/Share | $17.64 |
| Equity/Share | $124.45 |
Technical Indicators
| RSI (14) | 32.21 Neutral |
| MACD |
1.21
Signal: 2.71
|
| Volatility | 36.37% |
| Trading Signal | Bearish |
Performance & Returns
| 1 Year | +42.01% |
| Sharpe Ratio | 1.35 Good |
| Volatility (Ann.) | 32.72% Moderate |
| BIIB (1Y) | +42.01% |
| S&P 500 (1Y) | +13.03% |
| Alpha (Excess Return) | +28.98% |
Sector Comparison (Healthcare)
| Metric | BIIB | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | 20.94 | 27.79 | 32% |
| P/B Ratio | 1.48 | -19.55 | 23% |
| ROE (%) | 7.28% | -9.43% | 30% |
| Net Margin (%) | 13.18% | 9.24% | 57% |
| Stock Score | 605 | 542.0 | 76% |
| 1Y Return (%) | +42.01 % | +7.48 % | 87% |
📊 Historical Price Analysis (Last 200 Days)
Loading chart...
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BIIB | $183.82 | $186.95 | $188.12 | $190.33 | $182.77 | $154.04 | 32.21 | 1.21 | 36.37% | 387708 | Strong Short | Bearish Stack |
Candlestick Patterns
There wasn't any recognizable pattern for the BIIB stock
News Sentiment
| 📊 Ticker | 📰 Headline | 💭 Sentiment | 📡 Source | 🔗 URL |
|---|---|---|---|---|
| BIIB | Biogen Inc. $BIIB Shares Sold by Dimensional Fund Advisors LP | Neutral | defenseworld.net | Read More |
| BIIB | Josh Brown: Biotech growth stocks immune to disruption risk | Positive | 247wallst.com | Read More |
| BIIB | Here's Why Biogen Inc. (BIIB) is a Strong Value Stock | Neutral | zacks.com | Read More |
| BIIB | Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy | Neutral | globenewswire.com | Read More |
| BIIB | Biogen Inc. (BIIB) Presents at Leerink Global Healthcare Conference 2026 Transcript | Neutral | seekingalpha.com | Read More |
Recent Insider Trading
No recent insider trading data available for BIIB
Company Information
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
| CEO | Christopher A. Viehbacher |
| Employees | 7605 |
| Country | US |
| IPO Date | 1991-09-17 |
| Exchange | NASDAQ |
| Website | https://www.biogen.com |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
Similar Stocks (Healthcare - Drug Manufacturers - General)
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category